Cardio Diagnostics
CDIO
30 hedge funds and large institutions have $49.6M invested in Cardio Diagnostics in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
2.7% more ownership
Funds ownership: 0% → 2.7% (+2.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
+$4.64M |
| 2 |
KIM
Karpus Investment Management
Pittsford,
New York
|
+$4.52M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.28M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$3.59M |
| 5 |
MSU
Mizuho Securities USA
New York
|
+$3.45M |
Top Sellers
CDIO Hedge Fund Activity: Q1 2022 in Review
30 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q1 2022, worth a combined $49.6M.
Buyers outnumbered sellers: 30 funds opened new CDIO positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Saba Capital Management, opening a new position worth an estimated $4.64M.
- 30 institutional investors held Cardio Diagnostics (CDIO) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $49.6M of Cardio Diagnostics stock for Q1 2022.
- 30 funds opened new Cardio Diagnostics positions in Q1 2022 and 0 closed out, a net change of +30 holders.
- The largest Cardio Diagnostics buyer in Q1 2022 was Saba Capital Management, an estimated $4.64M added.
Based on aggregated 13F filings for Q1 2022.